UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 481

Sortiert nach

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

The New England journal of medicine, 2020-03, Vol.382 (12), p.1124-1135

2020

Volltextzugriff (PDF)

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

The New England journal of medicine, 2020-03, Vol.382 (12), p.1112-1123

2020

Volltextzugriff (PDF)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Journal of acquired immune deficiency syndromes (1999), 2020-12, Vol.85 (4), p.498

2020

Volltextzugriff (PDF)

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

Antimicrobial Agents and Chemotherapy, 2013-11, Vol.57 (11), p.5472-5477

2013

Volltextzugriff (PDF)

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744

Antimicrobial Agents and Chemotherapy, 2013-01, Vol.57 (1), p.277-280

2013

Volltextzugriff (PDF)

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10101), p.1499-1510

2017

Volltextzugriff (PDF)

Formulation and pharmacology of long-acting cabotegravir

Current opinion in HIV & AIDS, 2015-07, Vol.10 (4), p.239

2015

Volltextzugriff (PDF)

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

Journal of acquired immune deficiency syndromes (1999), 2014-12, Vol.67 (5), p.481

2014

Volltextzugriff (PDF)

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine

Therapeutic Advances in Infectious Disease, 2023-01, Vol.10

2023

Volltextzugriff (PDF)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

AIDS (London), 2021-07, Vol.35 (9), p.1333-1342

2021

Volltextzugriff (PDF)

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

AIDS (London), 2022-02, Vol.36 (2), p.185-194

2022

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

Journal of acquired immune deficiency syndromes (1999), 2014-12, Vol.67 (5), p.487

2014

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

Antimicrobial agents and chemotherapy, 2022-03, Vol.66 (3), p.e0205721-e0205721

2022

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants

Antimicrobial agents and chemotherapy, 2024-01, Vol.68 (1), p.e0078123-e0078123

2024

Volltextzugriff (PDF)

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

British journal of clinical pharmacology, 2022-10, Vol.88 (10), p.4607-4622

2022

Volltextzugriff (PDF)

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0005323-e0005323

2023

Volltextzugriff (PDF)

Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials

HIV medicine, 2023-05, Vol.24 (5), p.568-579

2023

Volltextzugriff (PDF)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis

British journal of clinical pharmacology, 2022-02, Vol.88 (4), p.1667-1678

2022

Volltextzugriff (PDF)

1 – 25 von 481

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(445)
Mit Volltextzugriff
(387)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Formulation and pharmacology of long-acting cabotegravir

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis

Suchergebnisse filtern